CN102811717A - Nutritional composition - Google Patents
Nutritional composition Download PDFInfo
- Publication number
- CN102811717A CN102811717A CN2011800162405A CN201180016240A CN102811717A CN 102811717 A CN102811717 A CN 102811717A CN 2011800162405 A CN2011800162405 A CN 2011800162405A CN 201180016240 A CN201180016240 A CN 201180016240A CN 102811717 A CN102811717 A CN 102811717A
- Authority
- CN
- China
- Prior art keywords
- alimentation composition
- fatty acid
- composition according
- alimentation
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is a nutritional composition which is suitable for administration by tube feeding such as enteral or gastric administration, or by oral ingestion, and which contains a high concentration of lipids, which are caloric nutrients capable of providing high calorific value. The nutritional composition also exhibits excellent emulsion stability, and excellent utilisation efficiency as a caloric nutrient. The disclosed nutritional composition uses lipids wherein the medium-chain fatty acid inclusion amount is 20-80 weight%, uses an emulsifier such as an organic acid monoglyceride or lecithin which has fatty acids in the structure thereof, and the composition is formed as an oil-in-water type emulsion composition.
Description
Technical field
The present invention relates to a kind of contain as the lipid that can supply with the heat composition of high heat be used as main constituent alimentation composition.More detailed, it is excellent to relate to a kind of emulsion stability, be fit to oral uptake, in pipe is granted any, can be used as the alimentation composition that medicine or diet article provide.
Background technology
At present, the commercially available liquid liquid food and the nutrient major part that are used for granting through pipe are adjusted at 1kcal/mL (g)～2kcal/mL (g) with heat.These alimentation compositions are mostly for can only carrying out the composition of nutritional care (particularly with artificial object in bedfast old age) with it in addition.These usually with each hundreds of mL, be divided in 1 day and grant for several times.
For example, need grant in every day under the situation of 1000kcal,, then can calculate,, need 10 hours, even if the preparation of 2kcal/mL also needs 5 hours for the liquid formulation that is adjusted into 1kcal/mL if grant with the speed of 100mL/h.Therefore hard to imagine with uncommon feed is promptly compared through the situation of oral uptake nutrition, and the needed time of nutrient is significantly elongated.Therefore produce a lot of shortcomings.If carry out illustration, then can enumerate out, (1) owing to be bound to long nutrition and grant, thereby the time of giving exercise therapy is restricted; (2) owing to utilized when the nutrition of pipe nutrition is granted and require certain position, thereby the risk that the disgrace skin ulcer takes place increases; (3) in most cases require nurse, helper etc., nursing staff to confirm the operation that the situation of granting is whether suitable at regular intervals, need the labour for this reason; (4) physiological function such as the passing of blood glucose value, gastric acid secretion state is replied and possibly prepared when managing nutrition, to produce under the situation of microbial contamination with different (5) that caused by common feed; Grant microorganism in the thing possibility of propagation, the risk rising that alimentary toxicosis takes place etc. are arranged.Therefore think and the needed time when seeking to shorten nutrition as much as possible grants, can bring preferred result.
But; Cause the patient that swallows, chew ability and reduce stomach dwindles as following the age to increase old people, by cerebrovascular disease, neuromuscular disease etc., cause under the situation the patient of oral uptake difficulty, the postoperative patient etc., that gastrointestinal function is weak by disturbance of consciousness etc.; Side effect such as GERD, diarrhoea be possibly cause, thereby a large amount of liquid foods or nutrient preferably once do not granted.
As the method that solves with alimentation composition the problems referred to above that produce when long-time or short time grants, can consider that it is low capacity that composition with alimentation composition is prepared into than in the past preparation higher concentration and preparation consumption.Through being prepared into high concentration, make its heat composition that contains abundant amount, through being prepared into low capacity, can alleviate burden to patient and nursing staff.But; As containing normally used comprehensive trophic component, being the preparation of protein, carbohydrate, lipid, mineral, vitamin; With the angle of its high concentrationization from preparation and ingredient stability; Be difficult, thus we can say preferably process mainly contain lipid, heat composition supply specialization the form of additional liquid.
As said high concentration and low capacity, with the supply of heat composition is that the per os enteral nutrition of purpose is used lipomul, and commercially available マ イ Network ロ リ ピ ッ De (" Microlipid " is arranged; ノ バ Le テ ィ ス society, registered trade mark).It is the lipid composition of safflower oil 100%, the liquid emulsion preparation of 4.5kcal/mL (lipid 50g/100mL), and its form is the vial of putting into through the screw lid sealing, and capacity is 89mL/.Aforementioned emulsification preparation is as the preferred fluid composition of heat composition supply purposes, but not special consideration fatty acid composition is not talkative good as the utilization ratio of heat composition; Carry out when pipe is granted, need be via other container, thereby from the viewpoint of health aspect, convenience; Poor availability does not have sufficient emulsion stability, easy separation during room temperature preservation; The capacity of one packing unit is many, low capacity is unhygienic etc. when using, the very preferred preparation of can not saying so.
On the other hand, as the lipomul that can easyly be used for granting, disclose preparation and avoided the technology (patent documentation 1,2) of liquid level in fact with the Prefilled syringe that contacts (Pre-filled Syringe) preparation of oxygen through pipe.But these technology only provide and are suitable for the preparation technique of granting through vein specially, do not relate to being suitable for through stomach or enteral nutrition.Disclosed in addition fill volume from the viewpoint of heat composition supply, is not carried out abundant detailed survey for number mL.For being the medicine preparation of representative with commercially available lipomul イ Application ト ラ リ ピ ッ De (テ Le モ Co., Ltd., registered trade mark), イ Application ト ラ リ Port ス (Otsuka Pharmaceutical Factory, Inc., registered trade mark); Be purpose also to grant through vein; Good aspect preparation stabilities such as juice secretion; But the lipid concentration that contains is 10% or 20%; With the LCFA is main constituent, and from the viewpoint of " preparation that contains the lipid of high concentration ", it is ideal through stomach or enteral nutrition preparation to say so.
In addition, as the technology of the preparation that relates to lipomul, patent documentation 3～5 has open.But; These mainly disclose the technology of about preparation stability, particularly being controlled the inhibition effect that is separated that causes by particle diameter; But, still, openly do not relate to the preferred technology that nutritional labeling is granted not about the investigation of lipid concentration from the viewpoint of granting of heat composition.Be combined with glucose, glycerol as emulsion stabilizer in the aforementioned in addition lipomul, according to its use level, by dispenser's state, per os and the risk that produces the diarrhoea problem is arranged when intestinal is granted.Therefore, be used to carry out technology, inadequate information disclosure is only arranged through stomach or enteral nutrition as ideal.And then owing to infer aforementioned lipomul for to grant through vein, the obstruction of the filter when granting should make the mean diameter of emulsified particle little, needs perhaps repeatedly emulsifying of high pressure during manufacturing.
In addition, as the technology of the external member that relates to liquid nutritional composition, have open in the patent documentation 6～8.These technology are characterised in that makes each nutritional labeling, preserve with isolating state separately; But not the external member that mainly is conceived to the supply of heat composition; Not about can low capacity and high concentration grant, particularly as the research of the raising of the utilization ratio of the lipid of heat composition.In addition, in the said external member, need mix multiple liquor during use, this operation is very miscellaneous sometimes.
That is, about containing the alimentation composition of the high lipid of high concentration and utilization ratio as single agent formula (a drug formula) of heat composition and emulsion stability excellence, up to the present not open very gratifying compositions.
The prior art document
Patent documentation
Patent documentation 1: TOHKEMY 2004-210688 communique
Patent documentation 2: TOHKEMY 2006-239048 communique
Patent documentation 3: japanese kokai publication hei 5-9111 communique
Patent documentation 4: japanese kokai publication hei 9-67246 communique
Patent documentation 5: japanese kokai publication hei 10-310517 communique
Patent documentation 6: japanese kokai publication hei 6-141819 communique
Patent documentation 7: TOHKEMY 2004-283117 communique
Patent documentation 8: TOHKEMY 2007-262088 communique.
Summary of the invention
The technical problem that invention will solve
Here; Problem of the present invention is; A kind of any alimentation composition that contains lipid as the heat composition of supplying with high heat, is suitable for oral uptake and grants etc. through stomach or through intestinal that warp pipe grants with high concentration is provided, and its emulsion stability is excellent, as the utilization ratio of heat composition also excellence.
The technological means of dealing with problems
The inventor etc. further investigate in order to solve above-mentioned problem, and the result finds to contain through use the lipid of the medium-chain fatty acid of ormal weight; As emulsifying agent; Use the emulsifying agent of concrete fatty acid in its structures such as lecithin and organic acid mono-glyceride, can obtain alimentation composition, it contains as the lipid heat composition, that utilization ratio is good with high concentration; Emulsion stability is excellent simultaneously, thereby has accomplished the present invention.
Promptly the present invention relates to following ［ 1 ］～［ 18 ］.
［ 1 ］ alimentation composition; It is that the medium-chain fatty acid content that contains in the lipid is the O/W emulsion composition that the lipid of 20 weight %～80 weight % and the emulsifying agent that in its structure, has fatty acid form, and the total content of said lipid and said emulsifying agent is 25 (w/v) %～65 (w/v) % with respect to total composition.
［ 2 ］ according to above-mentioned ［ 1 ］ described alimentation composition, wherein, the emulsifying agent that in its structure, has fatty acid be selected from lecithin and the organic acid mono-glyceride more than a kind or 2 kinds.
［ 3 ］ according to above-mentioned ［ 2 ］ described alimentation composition, wherein, organic acid mono-glyceride is the citric acid monoglyceride.
［ 4 ］ according to above-mentioned ［ 1 ］ or ［ 2 ］ described alimentation composition, wherein, the medium-chain fatty acid in the lipid is contained with the form of medium-chain fatty acid triglyceride.
［ 5 ］ according to above-mentioned ［ 1 ］ or ［ 2 ］ described alimentation composition, wherein, further contain be selected from saccharide and the glycerol more than a kind or 2 kinds.
［ 6 ］ according to above-mentioned ［ 5 ］ described alimentation composition, wherein, with respect to total composition, the content more than a kind or 2 kinds that is selected from saccharide and the glycerol is that 35 (w/v) are below the %.
［ 7 ］ according to above-mentioned ［ 6 ］ described alimentation composition, the alimentation composition that it is used for diabetics.
［ 8 ］ according to above-mentioned ［ 1 ］ or ［ 2 ］ described alimentation composition, wherein, the weight ratio that contains ω-3 in the lipid and be fatty acid and ω-6 and be fatty acid is the lipid of 1:10～10:1.
［ 9 ］ according to above-mentioned ［ 1 ］ or ［ 2 ］ described alimentation composition, wherein, for every 100kcal alimentation composition, the content of phosphorus is below the 20mg.
［ 10 ］ according to above-mentioned ［ 9 ］ described alimentation composition, the alimentation composition that it is used for the nephrotic.
［ 11 ］ according to above-mentioned ［ 1 ］ or ［ 2 ］ described alimentation composition, wherein, further contain be selected from protein, dietary fiber, vitamins and the minerals more than a kind or 2 kinds.
［ 12 ］ according to above-mentioned ［ 1 ］ or ［ 2 ］ described alimentation composition, its capacity with 10mL～100mL is a packing unit.
［ 13 ］ according to above-mentioned ［ 1 ］ or ［ 2 ］ described alimentation composition, it is filled with aseptic condition.
［ 14 ］ according to above-mentioned ［ 1 ］ or ［ 2 ］ described alimentation composition, the alimentation composition that it is used for oral uptake.
［ 15 ］ according to above-mentioned ［ 1 ］ or ［ 2 ］ described alimentation composition, it is for granting the alimentation composition of usefulness through stomach or through intestinal.
［ 16 ］ medicine, it contains each described alimentation composition in above-mentioned ［ 1 ］～［ 11 ］.
［ 17 ］ diet article, it contains each described alimentation composition in above-mentioned ［ 1 ］～［ 11 ］.
［ 18 ］ oral uptake is used the nutrient external member with perhaps granting through stomach or through intestinal, and it contains each described alimentation composition in comprehensive nutrient compositions and above-mentioned ［ 1 ］～［ 10 ］.
The invention effect
The emulsion stability of alimentation composition of the present invention is excellent, when preserving for a long time, does not observe the be separated variation of such emulsified state such as juice secretion (dried up), creaming (creaming) at least in 1 month.In addition, owing to contain as the good lipid of the utilization ratio of heat composition, can process low capacity, thereby also be suitable for oral uptake, any that warp pipe grants such as grant through stomach or through intestinal with high concentration, useful for the patient who needs the heat supply.
The specific embodiment
Alimentation composition of the present invention is to contain the high lipid of medium-chain fatty acid content with high concentration, carries out the O/W emulsion composition that emulsifying forms through the emulsifying agent that has fatty acid in its structures such as lecithin, organic acid mono-glyceride.
" lipid " that contain in the alimentation composition of the present invention is meant, as the fat of heat components utilising, i.e. oils.As said oils; The diet article just can use with what provide so long as use perhaps as medicine; Not special restriction; For example, can enumerate out American Avocado Tree oil, Semen Lini oil, almond oil, perilla oil, olive oil, cocoa butter, Oleum Vitis viniferae, Oleum sesami, Miyou, safflower oil, perilla oil, soybean oil, Chinese toon oil, Radix Oenotherae erythrosepalae oil, Semen Maydis oil, Oleum Brassicae campestris, rice oil, Petiolus Trachycarpi oil, palm kernel oil, Oleum Arachidis hypogaeae semen, Oleum Helianthi, hazelnut oil, Oleum Gossypii semen, Oleum Cocois, Caulis et Folium Lactucae Sativae wet goods vegetative grease class; Animal raw fat classes such as fish oil, chicken oil, Adeps Bovis seu Bubali, leaf fat, Adeps caprae seu ovis; Butter oil, butter, margarine oil's wet goods butterfat, processing oils and fats etc.Among the present invention, select use more than a kind or 2 kinds wherein.
Among the present invention, using the medium-chain fatty acid content in the lipid is the lipid of 20 weight %～80 weight %.Carbon numbers such as that " medium-chain fatty acid " of the present invention is meant is sad, capric acid, lauric acid are 8～12 fatty acid, these preferably in lipid the form with the medium-chain fatty acid triglyceride contained.Medium-chain fatty acid is compared with the LCFA that is present in usually in the oils; Have and digest and assimilate fast about 4 times; Do not pass through portal vein after the absorption and be transported to liver,, thereby can be suitable as the use of heat composition promptly by the such characteristic of metabolism through lymphatic vessel.Therefore, insufficient when the medium-chain fatty acid in the lipid contains quantity not sufficient 20 weight % as the utilization ratio of heat composition, thereby not preferred.On the other hand, when surpassing 80 weight %, the possibility that acidosis disease (acidosis) takes place along with the rising of ketoboidies in the blood is arranged.According to the object of the invention, can use " コ コ ナ ー De MT ", " コ コ ナ ー De RK ", " コ コ ナ ー De ML " (flower king ケ ミ カ Le system), " デ リ オ ス SJ ", " デ リ オ ス VJ " (コ グ ニ ス society system), " ア ク タ ー M-1 ", " ア ク タ ー M-107FR " (reason is ground PVC タ ミ Application society system) etc., conduct " medium-chain fatty acid triglyceride " commercially available product.In addition, also can use Oleum Cocois, Petiolus Trachycarpi oil, palm kernel oil, butter oil, butter etc. to contain the oils of medium-chain fatty acid morely.As Oleum Cocois or Petiolus Trachycarpi wet goods, also can use the oil that extraction, purification form from natural plants such as Cortex cocois radicis, but use commercially available article convenient.
Then, in the present invention, use the emulsifying agent that has fatty acid in its structure.The fatty acid that contains in the structure as emulsifying agent; Can enumerate out carbon numbers such as the fatty acid, particularly lauric acid that derive from Oleum Cocois, Petiolus Trachycarpi oil, soybean oil, Semen Allii Tuberosi wet goods Vegetable oil lipoprotein, myristic acid, Palmic acid, stearic acid and be carbon numbers such as about 12～18 satisfied fatty acid, oleic acid, linoleic acid, linolenic acid is unsaturated fatty acid of about 18 etc.As aforementioned emulsifying agent; Can enumerate out fatty acid glyceride (glycerine monofatty ester, fatty acid two glyceride), organic acid mono-glyceride, polyglyceryl fatty acid ester, polyglycereol condensation ricinoleate ester, Sorbitol fatty acid ester, sucrose fatty acid ester, lecithin etc., can use more than a kind or 2 kinds from wherein selecting as the derivant of aforementioned fatty acid glyceride.Particularly contain at least one that is selected from lecithin and the organic acid mono-glyceride in the emulsifying agent through making, water and oil phase did not produce composition isolated at least in 1 month in the time of can obtaining emulsion stability excellence, preservation.
Lecithin is meant the lipid goods that contain phospholipid (phospholipid), and can be used as the lecithin that emulsifying agent uses among the present invention can enumerate out, obtain by Semen sojae atricolor, be the soybean lecithin of main constituent with the phosphatidylcholine; The vegetable lecithin that obtains by the seed of Brassica campestris L etc.; The Ovum Gallus domesticus Flavus lecithin that obtains by egg yolk; Soybean lecithin, vegetable lecithin or Ovum Gallus domesticus Flavus lecithin are carried out the enzyme decomposition to be obtained, is the enzyme decomposition lecithin of main constituent with phosphatidic acid and/or LYSOLECITHIN SUNLECITHIN A; With sphingomyelins (Sphingomyelin), phosphatidylinositols (Phosphatidylinositol), PHOSPHATIDYL ETHANOLAMINE (phosphatidylethanolamine) and phosphatidylcholine is the fractionated lecithins of main constituent; The partial hydrolysis lecithin that the property hydrolysis of lecithin part is obtained, lecithin is carried out hydrogenation and the hydrolecithin that obtains, hydroxyl is imported in the lecithin and the chemical modification lecithin of the hydroxide lecithin that obtains etc. etc.Among the present invention, preferably use soybean lecithin, enzyme decompose in lecithin, the fractionated lecithins more than a kind or 2 kinds.
In addition, organic acid mono-glyceride is the derivant of the aforementioned monoglyceride that on the hydroxyl of the remnants of glycerine monofatty ester, combines organic acid and form.As the organic acid mono-glyceride that can be used as emulsifying agent, can enumerate out acetic acid monoglyceride, citric acid monoglyceride, mono succinate glyceride, diacetyl tartaric acid monoglyceride, lactic acid esters of mono etc. among the present invention.Among the present invention,, thereby most preferably use because the acidproof emulsifying of citric acid monoglyceride is excellent, also can be used as the auxiliary agent use of greasy antioxidant.
Further, as emulsifying agent, through with fatty glyceride, especially be preferably glycerine monofatty ester more than a kind or 2 kinds be selected from lecithin and the organic acid mono-glyceride more than a kind or 2 kinds and usefulness, can obtain good emulsifying stability.
In order to keep stable emulsifying, in the alimentation composition of the present invention, the total amount with respect to the lipid that uses is made as 5 weight %～40 weight % with the total amount that has the emulsifying agent of fatty acid in its structure, is preferably 10 weight %～30 weight.In addition, the total amount in them more than a kind or 2 kinds that is selected from lecithin and the organic acid mono-glyceride preferably contains 2 (w/v) %～26 (w/v) %, contains 30 weight %～100 weight % with respect to the total amount that has the emulsifying agent of fatty acid in its structure with respect to the alimentation composition total amount.
In the alimentation composition of the present invention; The total content that has the emulsifying agent of fatty acid in above-mentioned lipid and its structure is 25 (w/v) %～65 (w/v) % with respect to total composition; Be preferably 25 (w/v) %～55 (w/v) %, more preferably 30 (w/v) %～50 (w/v) %.
Also can use the emulsifying agent that do not contain fatty acid in its structure in addition, other have the raw material that stable emulsifying turns usefulness into, the for example gelating agent of agar, carrageenin etc., tackify polysaccharide; Phosphate, citrate etc. have the salt of chelation etc.Can consider storage stability, thermostability, absorbability, manufacturing cost etc., from wherein selecting more than a kind or 2 kinds, and decision use level and use level ratio.
From the viewpoint that the heat composition is carried out supply with preferred form, so long as do not produce the degree that rising, hyperosmosis by blood glucose value causes gastricism (diarrhoea etc.) problem, just can contain be selected from saccharic and the glycerol more than a kind or 2 kinds.But because alimentation composition of the present invention contains lipid with high concentration; Thereby through further containing saccharic etc. in a large number, water quantities reduces, makes right property, taste decline relatively sometimes, the bactericidal properties that causes, the simplicity when granting etc. suffer damage by the viscosity rising.Here, contain among the present invention be selected from saccharic and the glycerol more than a kind or 2 kinds the time, with respect to total composition, can be 35 (w/v) below the %, preferably be 10 (w/v) below the %.Among the present invention, not necessarily must contain saccharic.If as comprise through intravenous nutrition, other approach alimentation composition and in by dispenser's body, supply with the situation of saccharic, then through processing the compositions that does not contain saccharic, can the blood sugar control value.That is,, can form suitable heat composition supply source for diabetics through considering saccharic content.In addition, for the lung disease headed by the chronic occlusion property respiratory illness, has following advantage: can alleviate generation, can reduce ventilation load to lung by the two acidify carbon of granting the metabolic that saccharic causes.
As operable saccharic among the present invention, can enumerate out monosaccharides such as glucose, fructose; Disaccharides such as sucrose, maltose; Oligosaccharide classes such as oligofructose, galactooligosaccharicomposition, mannooligo saccharide, LS 55L; Polysaccharides such as dextrin, dextran, starch, glycogen; Sugar alcohols such as xylitol, Sorbitol, reduction dextrin etc.
When needing essential fatty acid in addition, the ω-3 in the preferred lipid is that fatty acid and ω-6 are that the weight ratio of fatty acid is 1:10～10:1, more preferably 1:4～4:1." ω-3 is a fatty acid " also is expressed as " n-3 is a fatty acid ", but illustration goes out alpha-linolenic acid, eicosapentaenoic acid, DPA DOCOSA-PENTENOIC ACID and docosahexenoic acid etc.Known eicosapentaenoic acid has the effect that improves insulin resistance, thereby can be more suitable for being used for the situation of diabetic nephropathy.Among the present invention, can be from wherein selecting use more than a kind or 2 kinds." ω-6 is a fatty acid " also is expressed as " n-6 is a fatty acid " in addition, but illustration goes out linoleic acid, gamma-Linolenic acid and arachidonic acid etc.Among the present invention, from wherein selecting use more than a kind or 2 kinds.
Above-mentioned ω-3 is that fatty acid is rich in perilla oil, Semen Lini oil, fish oil etc., and ω-6 is that fatty acid is rich in safflower oil, Oleum Helianthi, soybean oil, Oleum Brassicae campestris, Radix Oenotherae erythrosepalae wet goods, among the present invention, and can extraction from these oils, purification and using.In addition, also can use the material of making through chemical synthesis, fermentation method etc., also can use with the diet article with the commercially available article of selling.Further, as lipid source, also can directly use and be rich in aforementioned ω-3 is that fatty acid or ω-6 are the oils of fatty acid.And then to have said ω-3 in its structure be that fatty acid or ω-6 are the emulsifying agent of fatty acid through using, and can realize that above-mentioned fatty acid forms.Need to prove, among the present invention, be fatty acid as ω-3, from the viewpoint to the effect of various diseases associated with inflammation, especially preferably contains any one or the two of eicosapentaenoic acid and docosahexenoic acid.About ω-3 is that fatty acid and ω-6 are the weight ratio of fatty acid, according to the patient's who infers use nutritional status, with other alimentation compositions and time spent said composition in the essential fatty acid amount, the approach of granting of alimentation composition, greasy price, rank etc. that contain decide.
Among the present invention,, can provide the alimentation composition that can carry out suitable nutritional care in addition as nutrient preparation for the nephrotic through the content of adjustment phosphorus.The preferred every 100kcal alimentation composition of the content of phosphorus in this case is below the 20mg, more preferably below the 10mg.In order to adjust the use level of phosphorus, need adjust the use level that phosphate, phosphate ester etc. become the composition of phosphorus supply source, need the suitable consumption of stipulating the lecithin as the emulsifying agent use, LYSOLECITHIN SUNLECITHIN A etc.When the consumption of phospholipid is reduced, preferably organic acid mono-glyceride is replaced by phospholipid and uses.
In the alimentation composition of the present invention, can further add the heat composition of protein as other.As protein; Can enumerate out lactoproteins such as casein and salt, milk surum, soybean protein, aleuronat, corn protein, potato protein, fish meat protein, poultry meat protein, egg protein etc., also can use and be processed into powder, granule, lamellar or granulous material containing these proteinic raw materials in a large number.Also can use their hydrolysate in addition, also can from aminoacid and salt thereof, select to use more than a kind or 2 kinds.In addition, these protein can be that purpose cooperates to improve emulsion stability as required.
In addition, also can in alimentation composition of the present invention, add other nutritional labelings.As said nutritional labeling, can enumerate out dietary fiber, vitamins and minerals.
As dietary fiber, can enumerate out pectin, agarose, glucomannan, cellulose, indigestible dextrins etc., can be from wherein selecting use more than a kind or 2 kinds.Need to prove, based on the object of the invention, as dietary fiber, be not the material of 0kcal/g according to the Energy Conversion coefficient shown in MHLW's notice (No. the 0217002nd, No. the 0217001st, New Development of food, food New Development) preferably.As said dietary fiber, can enumerate out guar gum and its hydrolysate, indigestible dextrins, Fructus Tritici aestivi, soluble soybean dietary fiber etc.
As vitamins, can enumerate out retinol, retinal (Retinal), tretinoin vitamin A such as (Retinoic Acid); The carotenoid of beta-carotene etc.; Vitamin D such as vitamin D2, vitamin D3; Vitamin E such as alpha-tocopherol, γ-vitamin E; Fatsoluble vitamin classes such as vitamin K such as vitamin K1, Menaquinone K6, thiamine vitamin Bs such as (thiamin)
1, vitamin B such as riboflavin
2; Pyridoxol, 2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine., pyridoxamine vitamin Bs such as (pyridoxamine)
6; Vitamin Bs such as cobalamin
12; Nicotinic acid such as nicotinic acid, nicotinamide; Vitamin B groups such as pantothenic acid (pantothenic acid), biotin (biotin), folic acid; Water-soluble vitamins such as vitamin C.
As minerals, can enumerate out general minerals such as sodium, potassium, magnesium, calcium, phosphorus, iodine, ferrum, copper, manganese, selenium, zinc, chromium, molybdenum.Need to prove that when making the alimentation composition that the nephrotic uses, as described above, the phosphorus content of preferred every 100kcal alimentation composition is below the 20mg.
Need to prove that alimentation composition of the present invention preferably is prepared into high heat and low capacity in the no problem scope aspect compositions stable.Particularly, preferred for preparation becomes 2.5kcal/mL～6kcal/mL, more preferably is prepared into 3kcal/mL～5kcal/mL.
Can be as required in alimentation composition of the present invention, further add other medicines and use additive with perhaps food.As said additive, can enumerate out the pH regulator agent of citric acid, sodium citrate, acetic acid, sodium acetate, gluconic acid, sodium hydroxide etc.; Antioxidants such as arabo-ascorbic acid, butylated hydroxyanisole (BHA), propyl gallate; Correctivess such as aspartame, Radix Glycyrrhizae extract, glucide; Acidic flavoring agent such as lactic acid, succinic acid, tartaric acid, malic acid; Antiseptic such as sodium benzoate, sodium ethylene diamine tetracetate, sorbic acid, sodium sorbate, methyl parahydroxybenzoate, butyl p-hydroxybenzoate; Iron sesquioxide (Bengala), iron oxide yellow, iron oxide black, carmine, coloring agent such as edible blue No. 1, edible yellow No. 4, edible red No. 2 etc.
Alimentation composition of the present invention can directly provide or together contain, provides as medicine or diet article with carrier with medicine or diet article.As medicine, can form oral uptake and manage to grant with preparation or through warp such as stomach enteric nutrients and use preparation.In addition,, the normal food of emulsus or paste be can form, health functional foods such as specific food for health care, trophic function food, dietary supplement, other health food etc. are preferably as the diet article.
Need to prove; Under said situation; As alimentation composition of the present invention; So that the content more than a kind or 2 kinds that is selected from saccharic and the glycerol is the compositions that 35 (w/v) % following mode has been controlled with respect to total composition, can process medicine or diet article that diabetics is used through using.In addition, through using the compositions of having controlled as the mode below the 20mg with respect to every 100kcal alimentation composition with the content of phosphorus, can process medicine or diet article that the nephrotic uses.
The capacity of each packing of alimentation composition of the present invention does not have in the scope of obstacle aspect the heat of supply necessity from the inhibition of each consumption, microbial contamination, the viewpoint grade of the property handled, and is preferably low capacity.Particularly, be a packing unit preferably with 10mL～100mL, be a packing unit more preferably with 10mL～50mL.If a packing unit is aforementioned capacity, then will all measure under the situation that once the warp pipe is granted, need be careful injection rate hardly, the supply of carrying out sufficient heat composition is easy.
Capacity through with a packing unit of alimentation composition of the present invention is set at low capacity, grants favourable to what make the patient that established gastric fistula, intestinal fistula through pipe.Through popularizing rapidly of gastric fistula, intestinal fistula through the pipe alimentation, this be because this method than in the past to pass through the nutritional care that nasogastric tube carries out easier, thereby can improve patient's quality of life.If alimentation composition of the present invention is perhaps being granted middle use through intestinal fistula through gastric fistula; Then can expect to grant the needed time and be and to accomplish in several minutes; When granting necessary heat, while can the situation of observing shorten the enforcement time according to patient's state.In addition, owing to be health, garbage is also few, and it is easier to grant operation, thereby might further improve the quality of life.And then because easy the adjusting soaked into pressure, thereby also can reduce the diarrheal risk.In addition further, increase along with the age among the old people, the situation that stomach dwindles is more, and the amount of the feed that can absorb is extremely few, thereby low capacity and the alimentation composition of the present invention that contains the lipid of high concentration are useful.Particularly under the frequent situation that GERD takes place, the stomach volume dwindles, grants under the situation of finite capacity system, more can bring into play effect.In addition, under the situation via intestinal fistula, it is not preferred granting tart liquid object, thereby the pH of alimentation composition of the present invention is preferably 5～7.5, more preferably 5.5～6.8.Through with pH regulator near neutrality, the patient who coat of the stomach is had illness also can use, and can reduce the generation of side effect.
Container as the alimentation composition of filling low capacity; Preferably following container promptly has via through stomach enteral nutrition granting with the structure of managing the position use and can be connected with this pipe and inject, can wash in aforementioned tube through air or water or gel after possessing injection simultaneously through pipe with pipe etc.Remain aseptic through having such form and content liquid; Even, also can do one's utmost to avoid microbial contamination not being directly via situation about using, for example alimentation composition of the present invention is added under situation about using in the comprehensive nutrient liquid food or the situation that alimentation composition of the present invention is used as the external member preparation through pipeline.As the concrete shape of said container, the spuit shape container that can enumerate out through Prefilled syringe, utilizes blow molding or plural layers to carry out bag to form, have the container of disposable purposes of the bag etc. of mouthful bolt.
The material of said vesses such as Prefilled syringe is any one of glass and plastics, and is all no problem, but the safety when carrying and use, the viewpoint of offal treatment are preferably plastics.In addition, more preferably the transparency, light-proofness and thermostability good, can recycle, to the stable material of implant.As plastic resin, can enumerate out the resin that polysulfone resin, polyethersulfone resin, polyamide, polycarbonate resin, Corvic, acrylic resin, cyclic polyolefin resin, cyclic polyolefin copolymer resin, polymethylpentene resin, mylar, acrylic resin, polyvinyl resin, pet resin etc. have utilized cross linked polymer.In the gasket part, except plastics, also can use elasticity macromolecular materials such as rubber or elastomer, preferably be coated with the good rubber of sliding of siloxanes or fluororesin.In addition about granting the position that is connected with pipe with the warp pipe; In order to be suitable for different shape; Can form from leading section and begin that diameter dwindles gradually and the taper that extends, the seal of leading section is through processing the sealing that for example utilized various lids, having utilized chimeric, the part that cuts connecting portion of cap nut and opening (spout) shape to keep with the shape in Kaifeng.
In addition, " aseptic " is meant and do not have microorganism in the material in this description, under the situation of medicine preparation, is meant and satisfies the Pharmacopeia of Japan defined terms.Under the situation of diet article; Be meant and do not have food poisoning bacteria, infect sick pathogen, become the microorganism of the reason that addles etc.; The room temperature circulation down; Do not exist bring infect or addle, such microorganism of losses in economic advantages, what is called was killed the commercial aseptic meaning of the food (レ ト Le ト food) of bacterium.Said aseptic through aseptic filling, fill back autoclave sterilization processing etc. and realize.For alimentation composition of the present invention; Keep aseptic before just will using; In addition through be filled to be suitable for through the granting of being connected of pipeline, compositions, in the container of the washing of pipeline, the probability that produces microbial contamination greatly reduces, and can grant easily.
Alimentation composition of the present invention can with the combination of other alimentation compositions, as oral uptake with, or provide through stomach or through the nutrient external member of granting usefulness that intestinal is granted etc. through pipe.In the said external member,, can supply with more high heat with the comprehensive nutrient compositions and the time spent of comprehensive nutrient liquid food etc.Because alimentation composition of the present invention contains the lipid of high concentration and is low capacity, thereby may be limited to minimum with respect to the volumetrical increase of heating load.Therefore, under the conditional situation of the cubical content of the compositions of granting, more can bring into play effect.The rising of the situation of in addition diabetics being granted etc., blood glucose value becomes under the situation of problem; For alimentation composition of the present invention; Considered the compositions of saccharic addition through use; Can efficient supply with heat well, the change risk of blood glucose value is few simultaneously, and it is easy that patient's nutritional care becomes.
Alimentation composition of the present invention can obtain through utilizing common emulsification method to process O/W emulsion composition.For example; Add under the situation of water soluble ingredient; Heat that this composition mixes and the water that obtains in water,, add the oil-phase component that adds this composition and mixed to wherein adding lipid and emulsifying agent and then adding under the situation of oil-soluble composition; Use intimate mixing device, colloid mill (Coloid mills), high-pressure homogenizer, the processing that mixes, homogenizes such as (microfluidizer) of microjet homogenizer, prepare thus.Need to prove that emulsifier type, character according to using also can be added into aqueous phase with emulsifying agent.In addition, add the vitamins etc. of a part such to heat-labile composition the time, can add again, mix after emulsifying, the cooling carrying out.
The particle diameter of the emulsion particle of the alimentation composition that obtains can be measured through emulsion, micellar common particle size determination method, for example dynamic light scattering method, laser diffractometry etc.To alimentation composition of the present invention, use the laser diffraction and scattering method to measure mean diameter.
Alimentation composition of the present invention is filled in the containers such as said syringe, bag after preparation, carries out sterilization treatment.The composition that Biocidal treatment method is considered to contain in the alimentation composition, the container of filling select the stability of heat, pressure etc., for example can use through sterilization by saturated steam under pressure, filter Filtration, utilize the gas sterilization of ethylene oxide gas etc. etc.In addition, preferably sterilely fill alimentation composition through aseptic filling.
Embodiment
Below through embodiment the present invention is described at length.
［ embodiment 1 ］ alimentation composition
(1) according to the composition shown in the table 1, in the stainless steel cask of 3L (below be designated as A), measure 740g blending water, in hot bath, be heated to 70 ℃～80 ℃.Then, utilize TK ロ ボ ミ ッ Network ス (プ ラ イ ミ Network ス Co., Ltd. system), under the high-speed stirred condition of 3000rpm, add dextrin, dissolve.
(2) will put among the A as the soybean oil of edible oil and fat and medium-chain fatty acid triglyceride and as the powder lecithin (enzyme decomposition lecithin) and the glycerine monofatty ester of emulsifying agent.After then being settled to 2000mL, dissolve dispersion,, under the homogenization pressure of 70MPa, handle 2 times through high-pressure homogenizer up to becoming uniform state.
(3) be that the mode of 150g is filled in the aluminum bag with per 1 weight, the boiling sterilization that under 123 ℃, carried out 10 minutes is handled, and obtains alimentation composition.
Above-mentioned composition is preserved down at 25 ℃, and carried out second day of sterilization treatment,, under the condition of rotor No.1,12rpm, under 25 ℃, measure with rotary viscosimeter (" BH-80 ", Toki Sangyo Co., Ltd.'s system), the result is about 300cP.In addition, (LS13 320 to utilize laser diffraction and scattering method particle size distribution device; ベ ッ Network マ ン コ ー ル タ ー society system) measure mean diameter, the result is 0.19 μ m.PH is 5.8.
［ embodiment 2 ］ alimentation composition
(1) according to forming shown in the table 1, in the stainless steel cask of 3L (below be designated as B), measure blending water 740g, in hot bath, be heated to 70 ℃～80 ℃.Then, utilize TK ロ ボ ミ ッ Network ス (プ ラ イ ミ Network ス Co., Ltd. system) under the high-speed stirred condition of 3000rpm, add dextrin, dissolve.
(2) will put among the B as the soybean oil of edible oil and fat and medium-chain fatty acid triglyceride and as powder lecithin (enzyme decomposition lecithin), citric acid monoglyceride and the glycerine monofatty ester of emulsifying agent.After then being settled to 2000mL, dissolve dispersion,, under the homogenization pressure of 70MPa, handle 2 times through high-pressure homogenizer up to becoming uniform state.
(3) be that the mode of 150g is filled in the aluminum bag with per 1 weight, the boiling sterilization that under 123 ℃, carried out 10 minutes is handled.
With above-mentioned composition 25 ℃ preserve down and carry out sterilization treatment second day,, under the condition of rotor No.1,12rpm, under 25 ℃, measure with rotary viscosimeter (" BH-80 ", Toki Sangyo Co., Ltd.'s system), the result is about 180cP.In addition, (LS13 320 to utilize laser diffraction and scattering method particle size distribution device; ベ ッ Network マ ン コ ー ル タ ー society system) measure mean diameter, the result is 0.19 μ m.PH is 4.0.
[table 1]
Need to prove that for the alimentation composition of embodiment 1 and 2, the value of calculation of the phosphorus content of every 100kcal and the heat of every 1mL gathers and is shown in Table 1.
［ embodiment 3 ］ alimentation composition
(1) according to forming shown in the table 2, measure blending water 900g at the stainless steel cask of 3L (below be designated as C), in hot bath, be heated to 70 ℃～80 ℃.
(2) utilize TK ロ ボ ミ ッ Network ス (プ ラ イ ミ Network ス Co., Ltd. system), under the high-speed stirred condition of 3000rpm, will put among the C as the powder lecithin (enzyme decomposition lecithin) of emulsifying agent.In addition, after will being pre-mixed as soybean oil, medium-chain fatty acid triglyceride, Oleum Brassicae campestris and the refine fish oil of edible oil and fat and as the pasty state lecithin (soybean lecithin) of emulsifying agent and glycerine monofatty ester, put among the C.Need to prove that the use level of various edible oil and fat is a fatty acid with ω-3 in lipid is formed: ω-6 is that the mode of fatty acid=1:2.7 (weight ratio) is adjusted.After then being settled to 2000mL, dissolve dispersion,, under the homogenization pressure of 70MPa, handle 2 times through high-pressure homogenizer up to becoming uniform state.
(3) be that the mode of 150g is filled in the aluminum bag with per 1 weight, the boiling sterilization that under 123 ℃, carried out 10 minutes is handled.
Above-mentioned composition is preserved down at 25 ℃, and carried out second day of sterilization treatment,, under the condition of rotor No.1,12rpm, under 25 ℃, measure with rotary viscosimeter (" BH-80 ", Toki Sangyo Co., Ltd.'s system), the result is about 30cP.In addition, (LS13 320 to utilize laser diffraction and scattering method particle size distribution device; ベ ッ Network マ ン コ ー ル タ ー society system) measure mean diameter, the result is 0.29 μ m.PH is 6.0.
［ embodiment 4 ］ alimentation composition
(1) according to the composition shown in the table 2, in the stainless steel cask of 3L (below be designated as D), measure blending water 900g, in hot bath, be heated to 70 ℃～80 ℃.
(2) utilize TK ロ ボ ミ ッ Network ス (プ ラ イ ミ Network ス Co., Ltd. system), under the high-speed stirred condition of 3000rpm, will put among the D as the powder lecithin (enzyme decomposition lecithin) of emulsifying agent.In addition; After will being pre-mixed as soybean oil, medium-chain fatty acid triglyceride, Oleum Brassicae campestris and the refine fish oil of edible oil and fat and as pasty state lecithin (soybean lecithin), citric acid monoglyceride and the glycerine monofatty ester of emulsifying agent, put among the D.Need to prove that the use level of various edible oil and fat is a fatty acid with ω-3 in lipid is formed: ω-6 is that the mode of fatty acid=1:2.7 (weight ratio) is adjusted.After then being settled to 2000mL, dissolve dispersion,, under the homogenization pressure of 70MPa, handle 2 times through high-pressure homogenizer up to becoming uniform state.
(3) be that the mode of 150g is filled in the aluminum bag with per 1 weight, the boiling sterilization that under 123 ℃, carried out 10 minutes is handled.
Above-mentioned composition is preserved down at 25 ℃, and carried out second day of sterilization treatment,, under the condition of rotor No.1,12rpm, under 25 ℃, measure with rotary viscosimeter (" BH-80 ", Toki Sangyo Co., Ltd.'s system), the result is about 16cP.In addition, (LS13 320 to utilize laser diffraction and scattering method particle size distribution device; ベ ッ Network マ ン コ ー ル タ ー society system) measure mean diameter, the result is 0.20 μ m.PH is 4.3.
[table 2]
Need to prove,, the value of calculation of the heat of the phosphorus content of every 100kcal and every 1mL gathered be shown in Table 2 for the alimentation composition of embodiment 3 and 4.
The evaluation of the emulsion stability when ［ Test Example ］ preserves
For the alimentation composition of the foregoing description 1～4, with Microlipid (ノ バ Le テ ィ ス society; Registered trade mark), estimates the emulsion stability when preserving as comparative example.That is, the compositions of each alimentation composition of embodiment and comparative example at room temperature left standstill preserved 6 months, through the time observe emulsified state.Emulsified state is estimated according to following metewand, and its result is shown in table 3.
＜metewand＞
Zero; Do not confirm juice secretion and creaming
△; Confirm to have a small amount of juice secretion or creaming
*; Significant juice secretion or creaming are arranged without fail
[table 3]
Can be known that by table 3 alimentation composition of embodiment 1～4 all demonstrates good emulsifying stability, the 6th month compositions for embodiment 2 confirms to have a little juice secretion, is not separated but observe juice secretion etc. more than 3 months.On the other hand, the compositions of comparative example was observed being separated of a little in 1st month preserving, and the 2nd month, became significantly and was separated.
The industry utilizability
As previously discussed; According to the present invention, can provide emulsion stability excellent, with high concentration contain as the good lipid of the utilization ratio of heat composition and can process low capacity, be suitable for oral uptake, through stomach or warp such as grant through intestinal and manage any the alimentation composition in granting.Therefore, aforementioned alimentation composition is useful for the patient who needs heat to supply with.
The application is willing to that with the spy in japanese publication 2010-073639 is the basis, and its content all comprises in this manual.
Claims (18)
1. alimentation composition; It is that the medium-chain fatty acid content that contains in the lipid is the O/W emulsion composition that the lipid of 20 weight %～80 weight % and the emulsifying agent that in its structure, has fatty acid form, and the total content of said lipid and said emulsifying agent is 25 (w/v) %～65 (w/v) % with respect to total composition.
2. alimentation composition according to claim 1, wherein, the emulsifying agent that in its structure, has fatty acid be selected from lecithin and the organic acid mono-glyceride more than a kind or 2 kinds.
3. alimentation composition according to claim 2, wherein, organic acid mono-glyceride is the citric acid monoglyceride.
4. alimentation composition according to claim 1 and 2, wherein, the medium-chain fatty acid in the lipid is contained with the form of medium-chain fatty acid triglyceride.
5. alimentation composition according to claim 1 and 2, wherein, further contain be selected from saccharide and the glycerol more than a kind or 2 kinds.
6. alimentation composition according to claim 5, wherein, with respect to total composition, the content more than a kind or 2 kinds that is selected from saccharide and the glycerol is that 35 (w/v) are below the %.
7. alimentation composition according to claim 6, the alimentation composition that it is used for diabetics.
8. alimentation composition according to claim 1 and 2, wherein, the weight ratio that contains ω-3 in the lipid and be fatty acid and ω-6 and be fatty acid is the lipid of 1:10～10:1.
9. alimentation composition according to claim 1 and 2, wherein, for every 100kcal alimentation composition, the content of phosphorus is below the 20mg.
10. alimentation composition according to claim 9, the alimentation composition that it is used for the nephrotic.
11. alimentation composition according to claim 1 and 2, wherein, further contain be selected from protein, dietary fiber, vitamins and the minerals more than a kind or 2 kinds.
12. alimentation composition according to claim 1 and 2, its capacity with 10mL～100mL is a packing unit.
13. alimentation composition according to claim 1 and 2, it is filled with aseptic condition.
14. alimentation composition according to claim 1 and 2, the alimentation composition that it is used for oral uptake.
15. alimentation composition according to claim 1 and 2, it is for granting the alimentation composition of usefulness through stomach or through intestinal.
16. medicine, it contains claim 1 or 2 described alimentation compositions.
17. the diet article, it contains claim 1 or 2 described alimentation compositions.
18. oral uptake is used the nutrient external member with perhaps granting through stomach or through intestinal, it contains comprehensive nutrient compositions and claim 1 or 2 described alimentation compositions.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010073639 | 2010-03-26 | ||
| JP2010-073639 | 2010-03-26 | ||
| PCT/JP2011/057453 WO2011118810A1 (en) | 2010-03-26 | 2011-03-25 | Nutritional composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102811717A true CN102811717A (en) | 2012-12-05 |
Family
ID=44673350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800162405A Pending CN102811717A (en) | 2010-03-26 | 2011-03-25 | Nutritional composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPWO2011118810A1 (en) |
| CN (1) | CN102811717A (en) |
| WO (1) | WO2011118810A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107205453A (en) * | 2015-04-22 | 2017-09-26 | 日清奥利友集团株式会社 | Gel-form composition and its manufacture method |
| CN108208798A (en) * | 2017-12-29 | 2018-06-29 | 北京康爱营养科技股份有限公司 | Full nutrient formulation liquid and preparation method thereof |
| CN108208839A (en) * | 2016-12-22 | 2018-06-29 | 费森尤斯卡比德国有限公司 | High heat liquid nutritional emulsion comprising lipid |
| CN109996561A (en) * | 2016-11-30 | 2019-07-09 | 狮王株式会社 | Oral preparation |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2820960A1 (en) | 2010-12-29 | 2012-07-05 | Abbott Laboratories | Nutritional products including a novel fat system including monoglycerides |
| JP5767981B2 (en) * | 2012-01-13 | 2015-08-26 | 森永乳業株式会社 | Liquid nutritional composition for patients with kidney disease |
| WO2013151081A1 (en) * | 2012-04-04 | 2013-10-10 | 大正製薬株式会社 | Aqueous liquid beverage |
| JP6059007B2 (en) * | 2012-12-26 | 2017-01-11 | キユーピー株式会社 | Water-soluble powder component-dispersed high nutrition composition and method for producing the same |
| WO2014160335A1 (en) | 2013-03-13 | 2014-10-02 | Abbott Laboratories | Infant nutritional product with rrr alpha-tocopherol |
| EP2983516A1 (en) | 2013-03-13 | 2016-02-17 | Abbott Laboratories | A composition for enhancing newborn infant cognitive, brain and/or cns development and method of using same |
| WO2016010008A1 (en) * | 2014-07-16 | 2016-01-21 | 日清オイリオグループ株式会社 | Oil and fat composition for assisting ingestion of foods for persons having swallowing and/or chewing difficulties, and foods for persons having swallowing and/or chewing difficulties |
| JP6659928B2 (en) * | 2015-11-26 | 2020-03-04 | アイドゥ株式会社 | Neutral nutrients high in fine particle emulsified fats and oils |
| JP6292357B2 (en) * | 2016-03-03 | 2018-03-14 | 不二製油株式会社 | Vegetable juice |
| CN107660793A (en) * | 2016-07-29 | 2018-02-06 | 费森尤斯卡比德国有限公司 | Nutrient powder and its production method |
| WO2018179952A1 (en) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | High-calorie nutritional composition, and package |
| WO2018179955A1 (en) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | Package |
| JP7084926B2 (en) * | 2017-07-21 | 2022-06-15 | テルモ株式会社 | High calorie nutritional composition and packaging |
| CA3108738A1 (en) | 2018-09-21 | 2020-03-26 | Societe Des Produits Nestle S.A. | Compositions and methods for treatment of exocrine pancreatic insufficiency (epi) |
| WO2020193385A1 (en) | 2019-03-22 | 2020-10-01 | Société des Produits Nestlé S.A. | Methods using medium chain triglycerides administered prior to a meal to decrease postprandial glucose from the meal |
| WO2022270369A1 (en) * | 2021-06-24 | 2022-12-29 | 森永乳業株式会社 | Nutritional composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0510687A2 (en) * | 1991-04-26 | 1992-10-28 | The Green Cross Corporation | Infusion preparation |
| CN101244037A (en) * | 2007-02-12 | 2008-08-20 | 广州富邦医药科技有限公司 | High concentration middle/long fatty milk injection for injection and preparing method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2935573A1 (en) * | 1979-09-03 | 1981-03-19 | Lepharm- Pharmazeutische Entwicklungs- und Vertriebsgesellschaft GmbH, 5000 Köln | Infusion solns. contg. fatty acid mono-and opt. di-glyceride - opt. with medium chain fatty acid tri:glyceride and emulsifier for improved stability |
| JPS61135572A (en) * | 1984-12-07 | 1986-06-23 | Nippon Oil & Fats Co Ltd | Fat emulsion for intestinal use |
| JP2542515B2 (en) * | 1987-05-28 | 1996-10-09 | 日清製油株式会社 | Therapeutic food |
| JP2950348B2 (en) * | 1991-04-27 | 1999-09-20 | 吉富製薬株式会社 | Fat emulsion and method for producing the same |
| US5470839A (en) * | 1993-04-22 | 1995-11-28 | Clintec Nutrition Company | Enteral diet and method for providing nutrition to a diabetic |
| JPH09157179A (en) * | 1995-12-04 | 1997-06-17 | Terumo Corp | Liquid nourishing composition |
| JP4925458B2 (en) * | 2007-12-13 | 2012-04-25 | 日清オイリオグループ株式会社 | Oil composition for cream and cream containing the oil composition |
-
2011
- 2011-03-25 JP JP2012507116A patent/JPWO2011118810A1/en active Pending
- 2011-03-25 CN CN2011800162405A patent/CN102811717A/en active Pending
- 2011-03-25 WO PCT/JP2011/057453 patent/WO2011118810A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0510687A2 (en) * | 1991-04-26 | 1992-10-28 | The Green Cross Corporation | Infusion preparation |
| CN101244037A (en) * | 2007-02-12 | 2008-08-20 | 广州富邦医药科技有限公司 | High concentration middle/long fatty milk injection for injection and preparing method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107205453A (en) * | 2015-04-22 | 2017-09-26 | 日清奥利友集团株式会社 | Gel-form composition and its manufacture method |
| CN107205453B (en) * | 2015-04-22 | 2021-08-10 | 日清奥利友集团株式会社 | Gel composition and method for producing same |
| CN109996561A (en) * | 2016-11-30 | 2019-07-09 | 狮王株式会社 | Oral preparation |
| CN108208839A (en) * | 2016-12-22 | 2018-06-29 | 费森尤斯卡比德国有限公司 | High heat liquid nutritional emulsion comprising lipid |
| CN108208798A (en) * | 2017-12-29 | 2018-06-29 | 北京康爱营养科技股份有限公司 | Full nutrient formulation liquid and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011118810A1 (en) | 2011-09-29 |
| JPWO2011118810A1 (en) | 2013-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102811717A (en) | Nutritional composition | |
| CN103504293B (en) | Liquid nutritional composition | |
| US9433586B2 (en) | Methods of improving tolerance related to feeding in an infant, toddler, or child | |
| ES2635764T3 (en) | Production method of a functional food product based on egg yolk and products obtainable by it | |
| JP5373227B1 (en) | Method for producing nutritional composition | |
| CN104379176B (en) | Semisolid nutrient | |
| CN104955344A (en) | Nutritional compositions comprising neuroprotective dietary oligosaccharides | |
| KR20100016608A (en) | Acidified liquid human milk supplement | |
| JP2014223081A (en) | Emulsified food composition | |
| KR20120104382A (en) | Liquid food composition | |
| JP6424937B2 (en) | Method for producing oil-in-water emulsion food composition and additive for oil-in-water emulsion food composition | |
| CN108601813A (en) | Include the high heat high protein nutrient formulation object of collagen | |
| CN101965136B (en) | Induced viscosity nutritional emulsions comprising a carbohydrate-surfactant complex | |
| JP4513157B2 (en) | Rich liquid food with soft bag | |
| CN104981169A (en) | Liquid concentrated human milk fortifier containing hypoallergenic protein and lutein | |
| JP4634757B2 (en) | Emulsified liquid enteral nutrient | |
| JP6012327B2 (en) | Emulsified nutritional composition | |
| JP2824598B2 (en) | Nutrition composition | |
| JPS6156061A (en) | Milky, nutritive composition | |
| JPH03117472A (en) | Administration bag type fluid diet | |
| JP7524490B2 (en) | Liquid nutritional composition and packaging | |
| US12096785B2 (en) | Lipid emulsion nutritional product | |
| JP2022154097A (en) | Semi-solid nutritional composition | |
| KR20240154079A (en) | Liquid nutritional composition and packaging | |
| JPWO2013125067A1 (en) | Semisolid nutrient for gastrostoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121205 |